OMNI Medical Services, LLC   Report issue

For profit Phase 2
Founded: Waterford MI United States (2012)
Status: No NME R&D (2012)

Organization Overview

First Clinical Trial
2018
NCT03944447
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

OMNI Medical Services | OMNI Medical Services, LLC

Active Ingredients

Drugs in Phase 2 Trials (1)

cannabis (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Anemia, Sickle Cell (Phase 2)

Bipolar Disorder (Phase 2)

Brain Diseases (Phase 2)

Brain Injuries (Phase 2)

Brain Injuries, Traumatic (Phase 2)

Chronic Pain (Phase 2)

Chronic Traumatic Encephalopathy (Phase 2)

Crohn Disease (Phase 2)

Disease (Phase 2)

Fibromyalgia (Phase 2)

Inflammatory Bowel Diseases (Phase 2)

Motor Neuron Disease (Phase 2)

Multiple Sclerosis (Phase 2)

Parkinson Disease (Phase 2)

Sclerosis (Phase 2)

Seizures (Phase 2)

Stress Disorders, Post-Traumatic (Phase 2)

Stress Disorders, Traumatic (Phase 2)

Syndrome (Phase 2)

Tourette Syndrome (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1